TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01338935
Drug: CW 002
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.
Study: NCT00385463
Drug: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01688635
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01688635
Drug: US Approved Lantus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00702910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT00702910
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug or placebo
Study: NCT00685841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID MDI
Study: NCT05918588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT02598635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
Study: NCT01593228
Drug: Doxorubicin HCL liposome injection
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Study: NCT04169854
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Study: NCT03321318
Drug: AK-R215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product is prescribed to all ofrandomized subjects
Study: NCT03428451
Drug: NaCl 3% HS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
Study: NCT03428451
Drug: NaCl 3% HS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
Study: NCT03428451
Drug: NaCl 0.9% NS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
Study: NCT01503632
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00119171
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00895453
Drug: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
Study: NCT02071069
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
Study: NCT01183455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusions of placebo once a week for 12 weeks.
Study: NCT02414958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04414566
Drug: gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT02215824
Drug: BIWH 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03256071
Drug: Modified BUCY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Study: NCT01294982
Drug: AOBO-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
Study: NCT01331720
Drug: hMG-HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00373100
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00373100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01319019
Drug: GSK961081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different doses and dosing regimens of the drug
Study: NCT01319019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT03926338
Drug: Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
Study: NCT02692313
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose response of epinephrine infusion
Study: NCT01146951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Study: NCT02762331
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing safety and efficacy of IV Vitamin C in CABG patients
Study: NCT02762331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention
Study: NCT01446679
Drug: atrovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01187836
Drug: TRV120027
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
Study: NCT01187836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 14 hours.
Study: NCT03342937
Drug: Oxaliplatin+Capecitabine+Pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.
Study: NCT01329289
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intramuscularly (IM) on day 1 of each 28 day cycle
Study: NCT02728388
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements
Study: NCT03637517
Drug: DSM265-TPGS 34% SDD, 400 mg fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
Study: NCT03637517
Drug: DSM265-TPGS 34% SDD, 400 mg fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
Study: NCT03637517
Drug: DSM265 25% SDD, 400 mg fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation used in early clinical trials.
Study: NCT03181841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blind oral intake of single doses of the aforementioned drug or placebo
Study: NCT04426994
Drug: proton pump inhibitor use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using long term proton pump inhibitor
Study: NCT02504177
Drug: novel oral anticoagulant for 30 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Study: NCT02504177
Drug: novel oral anticoagulant for 24 hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Study: NCT03836352
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO (BID)
Study: NCT02126670
Drug: Comp01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02126670
Drug: Comp02
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02126670
Drug: Comp03
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02126670
Drug: Comp04
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04183387
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00665678
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment for three months with placebo
Study: NCT00003595
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003595
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003595
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03357666
Drug: HUDC_VT(Glucose 200mg/Sodium chloride 200mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT03357666
Drug: HUDC_VT (Glucose 400mg/Sodium chloride 200mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT03357666
Drug: HUDC_VT (Glucose 400mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT03357666
Drug: HUDC_VT (Sodium chloride 200mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT03357666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT00418730
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Normalized name: tetrapeptide-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Study: NCT04087408
Drug: Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU.
Study: NCT00424346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182413
Drug: THN102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00647257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Study: NCT00154219
Drug: Lumiracoxib (drug)
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04036929
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT02541734
Drug: Gelofusine
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of gelofusine
Study: NCT02541734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00180843
Drug: nebulized saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02542787
Drug: VSN16R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule
Study: NCT02022436
Drug: Contrast Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
Study: NCT01433471
Drug: Trichuris suis ova
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,500 eggs by mouth every two weeks for 12 weeks
Study: NCT04604756
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo (oral)
Study: NCT03246451
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-4 tablets in 14 days
Study: NCT01601418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
Study: NCT00576589
Drug: CE-326,597
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
Study: NCT00576589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
Study: NCT04499989
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
Study: NCT04883034
Drug: Analgesics, etoricoxibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: anaelgetic oral intake
Study: NCT01753167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study: NCT01900743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
Study: NCT00445770
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: up to 8 mg per week, oral dosing for 52 weeks
Study: NCT05532280
Drug: Etoricoxib 90 mg film coated tablet
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Study: NCT05532280
Drug: Arcoxia 90 mg film coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Study: NCT02927938
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine-based consolidation chemotherapy
Study: NCT03797456
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
Study: NCT05840536
Drug: Furosemide plus Chlorothiazide
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs.
Study: NCT00551603
Drug: continuation (darbepoetinum)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuation of the previous darbepoetinum administration schedule
Study: NCT01831674
Drug: GLUCOPHAGE®XR tablet 750 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLUCOPHAGE®XR 750 mg once a day
Study: NCT04616222
Drug: CELSIOR® group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
Study: NCT04616222
Drug: Saint-Thomas group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
Study: NCT04751188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet every 12 hours for six months.
Study: NCT01270438
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01270438
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01270438
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01270438
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00856193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
Study: NCT00518271
Drug: Rapamune® (Sirolimus)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518271
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative
Study: NCT01673620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet administered once daily
Study: NCT04397562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02522325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will contain only cornstarch.
Study: NCT04500886
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
Study: NCT03458650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT03885661
Drug: Icosapent Ethyl 1000 MG [Vascepa]
Normalized name: icosapent ethyl 1000 MG [Vascepa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
Study: NCT00003476
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01883869
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01984736
Drug: Experimental: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, orally, once daily for up to six weeks.
Study: NCT00944216
Drug: Salkera Emollient Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of the Salkera emollient foam twice a day during the 12 week study period.
Study: NCT03943446
Drug: TAK-018 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-018 placebo-matching tablets.
Study: NCT03200093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ora-Sweet 5mL taken by mouth once daily.
Study: NCT02467023
Drug: Muscle Biopsy Medication: Versed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.